United Therapeutics (NASDAQ:UTHR) Issues Earnings Results, Beats Estimates By $0.23 EPS

United Therapeutics (NASDAQ:UTHR) posted its quarterly earnings results on Wednesday. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23, Briefing.com reports. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same period in the prior year, the business earned $5.38 EPS. The firm’s revenue for the quarter was up 22.9% on a year-over-year basis.

United Therapeutics Stock Performance

NASDAQ UTHR traded up $9.41 on Thursday, hitting $370.81. 308,491 shares of the stock traded hands, compared to its average volume of 465,486. The business’s fifty day moving average is $354.34 and its two-hundred day moving average is $315.28. United Therapeutics has a 12 month low of $208.62 and a 12 month high of $377.03. The firm has a market capitalization of $16.45 billion, a price-to-earnings ratio of 17.12, a PEG ratio of 1.27 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on UTHR shares. HC Wainwright increased their price objective on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday. Bank of America lowered their price objective on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research note on Thursday, August 1st. Argus increased their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday. Oppenheimer increased their price objective on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. Finally, LADENBURG THALM/SH SH downgraded United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $366.23.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $324.73, for a total transaction of $1,169,028.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $42,214.90. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $324.73, for a total value of $1,169,028.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $42,214.90. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 269 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $45,293.30. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 107,012 shares of company stock valued at $36,767,286. Company insiders own 12.50% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.